Protease-activated receptor 1 mRNA (PAR1 mRNA)

Protease-activated receptor 1 (PAR1) mRNA is the messenger RNA transcript of the F2R gene, which encodes the primary receptor for thrombin on human platelets and vascular cells (Source: UniProt P25116). As a member of the G protein-coupled receptor family, the translated PAR1 protein is uniquely activated through proteolytic cleavage of its extracellular N-terminus, revealing a tethered ligand that initiates downstream signaling (Source: PubMed PMID: 16407410). Targeting the mRNA transcript represents a therapeutic strategy to reduce the total cellular pool of PAR1, thereby dampening thrombin-mediated responses such as platelet aggregation, vascular inflammation, and cellular proliferation (Source: PubMed PMID: 23568255). This approach is under investigation for its potential to treat conditions characterized by PAR1 overactivity, including arterial thrombosis and various forms of cancer where PAR1 facilitates tumor progression and metastasis (Source: PubMed PMID: 11544174). Unlike small-molecule antagonists that compete for the receptor's binding site, mRNA-targeted therapies like siRNAs or antisense oligonucleotides provide a method for sustained downregulation of the receptor's expression (Source: PubMed PMID: 28258154).

Other names

F2R mRNACoagulation factor II receptor mRNAThrombin receptor mRNAPAR-1 mRNAProtease-activated receptor 1 transcript

Targeting PAR1 mRNA typically involves RNA interference (siRNA) or antisense oligonucleotides (ASOs) that lead to the degradation of the mRNA transcript or the inhibition of its translation, thereby reducing the density of PAR1 receptors on the cell surface (Source: PubMed PMID: 23568255, 28258154).